Comparison of Cost Per Response Between Deucravacitinib and Apremilast/Biologics in Patients with Moderate to Severe Plaque Psoriasis
Sang Hee Park, Mark Lambton, Jordana Schmier, Dipen Patel, Sara Hovland, Keith Wittstock, Vardhaman Patel
Comparison of overall pharmacy cost between deucravacitinib and branded systemic treatments among patients with moderate to
severe plaque psoriasis in the US
Sang Hee Park, Mark Lambton, Jordana Schmier, Dipen Patel, Sara Hovland, Keith Wittstock, Vardhaman Patel
Deucravacitinib in plaque psoriasis: 2-year laboratory results from the phase 3 POETYK PSO program
Neil J Korman, Thierry Passeron, Kenneth B Gordon, Yukari Okubo, Jerry Bagel, Howard Sofen, Richard B Warren, Neal Bhatia, Lynda Spelman, Kevin Winthrop, Joannee Zumkehr, Lauren Hippeli, Renata M Kisa, Subhashis Banerjee, Diamant Thaçi
Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program
Richard B Warren, Howard Sofen, Shinichi Imafuku, Jacek C Szepietowski, Andrew Blauvelt, Lynda Spelman, Joannee Zumkehr, Jessica Toms, Alex Buck, Subhashis Banerjee, Alan Menter
​Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO study program
Mark Lebwohl, Richard B Warren, Howard Sofen, Shinichi Imafuku, Carle Paul, Jacek C Szepietowski, Lynda Spelman, Thierry Passeron, Joannee Zumkehr, Elizabeth Colston, Lauren Hippeli, Andrew Napoli, Renata M Kisa, Subhashis Banerjee, Alan Menter, Diamant Thaçi, Andrew Blauvelt
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, versus placebo in scalp, nail, and palmoplantar psoriasis: subset analyses of the phase 3 POETYK PSO-1 and POETYK PSO-2 trials
Andrew Blauvelt, Phoebe Rich, Howard Sofen, Jo Lambert, Joseph F Merola, Mark Lebwohl, Joannee Zumkehr, Lauren Hippeli, Renata M Kisa, Subhashis Banerjee, Alexa B Kimball
Effectiveness, safety, and patient-reported outcomes from Week 28 of a Phase 4 study of tildrakizumab in patients with moderate-to-severe psoriasis
Neal Bhatia, Jayme Heim, Brad Schenkel, Stephen J Rozzo, J Gabriel Vasquez
Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial
Andrew Blauvelt, Javier Alonso-Llamazares, Neal Bhatia, Zoe D. Draelos, Janet DuBois, Seth B. Forman, Melinda Gooderham, Scott T. Guenthner, Adelaide A. Hebert, Edward Lain, Angela Y. Moore, Kim A. Papp, Linda Stein Gold, Matthew Zirwas, Saori Kato, Scott Snyder, David Krupa, Patrick Burnett, David R. Berk,David H. Chu
Efficacy of clascoterone cream 1% through up to 12 months from a long-term extension study in patients ≥9 years of age with acne vulgaris
Lawrence F. Eichenfield, Adelaide A. Hebert, Linda Stein Gold, Martina Cartwright, Luigi Moro, Jenny Han, Nicholas Squittieri, Alessandro Mazzetti
Efgartigimod: A Novel FcRn Antagonist in the Treatment of Autoimmune Diseases
Olga Ostrovskaya, Peter Ulrichts, Lance Trainor, Peter Verheesen, Ivaylo Stoykov
Pooled Efficacy and Safety Results From the DERMIS-1 and DERMIS-2 Phase 3 Trials of Once-Daily Roflumilast Cream 0.3% for Treatment of Chronic Plaque Psoriasis
Mark Lebwohl, Melinda J. Gooderham, Scott T. Guenthner, H. Chih-hoHong, Leon H. Kircik, Angela Y. Moore, Matthew Zirwas, Amy Feng, Robert C. Higham, Patrick Burnett, David R. Berk
A Unique Presentation of Merkel Cell Carcinoma with Metastases to the Peritoneum and Lung
Chandana Papudesu MD, Marvi Iqbal MD, MPH, Thiri Khin MD, Ajit Maniam MD
Anifrolumab Use in Rowell Syndrome: A Case Presentation with Marked Improvement
​​Chelsea Shope, MSCR; Laura Andrews, MSCR; Michael Knabel, MD; Melissa Cunningham, MD, PhD; Jessica S. Connett, MD
Intravenous Omadacycline as an Adjuvant Therapy to Ertapenem for Hidradenitis Suppurativa
​Peter Y. Ch’en, BS, Avigdor Nosrati, BS, McCall E. Torpey, BS, Michelle Toker, BS, Kristina L. Campton, MD, Steven R. Cohen, MD, MPH
Annual Trends in Medicare Part D Prescription Claims for Dupilumab 2017 to 2019
Leena Munawar MD, Aislyn OuleeBS, Alexandra Norden BS, Jacob P. Thyssen MD PhD,Jashin J. Wu MD
Non-Medical Switching in Dermatology
​Palak V Patel, BA; Caitlin G. Purvis, MD; Ramiz N. Hamid, MD, MPH; Steven R. Feldman, MD, PhD
Oral Linezolid as a Novel Treatment Modality for Advanced Hidradenitis Suppurativa
Michelle Toker BS, Peter Y. Ch’en BS, McCall Torpey MS, Avigdor Nosrati BS, Kristina L. Campton MD, Steven R. Cohen MD, MPH
Racial and Ethnic Disparities in Malignant Melanoma: A Literature Review
Mitchell Taylor, Robin Farias-Eisner, MD, PhD, MBA
Sarecycline as a Novel Treatment Modality for Hidradenitis Suppurativa: A Clinical and Patient Perspective
Peter Y. Ch’en, BS, Avigdor Nosrati, BS, McCall E. Torpey, BS, Michelle Toker, BS, Steven R. Cohen, MD, MPH, Kristina L. Campton, MD
Skin Cancer Development in Pediatric Patients Following Solid Organ Transplant
Laura Andrews, MSCR, Chelsea Shope, MSCR, Nicholas Strat, BS, Lara Wine Lee, MD, PhD